Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21135963 | 0.88 | GABBR2 (0.36) | GABBR2GABBR1HSD11B1LMNADHFR | |
| SCHEMBL21135972 | 0.84 | GABBR2 (0.39) | GABBR2GABBR1HSD11B1LMNADHFR | |
| SCHEMBL21135965 | 0.83 | GABBR2 (0.35) | GABBR2GABBR1ALDH1A1GABRB1GABRB2 | |
| SCHEMBL21135772 | 0.81 | CA12 (0.40) | GABBR2GABBR1LMNADHFRALDH1A1 | |
| SCHEMBL21135966 | 0.81 | ALDH1A1 (0.43) | GABBR2GABBR1HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17805514 | 0.80 | CYP19A1 (0.40) | LMNAALDH1A1HTTTSHRNPSR1 | |
| SCHEMBL21135968 | 0.78 | EPHX1 (0.37) | GABBR2GABBR1HSD11B1LMNAALDH1A1 | |
| SCHEMBL16724520 | 0.78 | ALDH1A1 (0.40) | GABBR2GABBR1HSD11B1LMNAALDH1A1 | |
| SCHEMBL21135998 | 0.75 | CYP17A1 (0.42) | HSD11B1LMNADHFRALDH1A1MAPT | |
| SCHEMBL21136401 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190196326-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD OF MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190196326-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD OF MANUFACTURING ELECTRONIC DEVICE | RER1, ACTR5, RAD51 | GABBR2 1946/4885GABBR1 2031/4885HSD11B1 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.